in this issue
Pharma/fine chemicals roundup—23 October
9:17 AM MDT | October 23, 2012 | By DEEPTI RAMESH AND LINDSAY FROST
Mylan buys API plant in India
Active pharmaceutical ingredients (API), intermediates and formulations manufacturer SMS Pharmaceuticals (Hyderabad, India) informed the Bombay Stock Exchange (Mumbai) that its board of directors has decided to sell its plant at Visakhapatnam, India, to Mylan Laboratories (Hyderabad), a subsidiary of Mylan (Canonsburg, PA), for 1.73 billion Indian rupees ($33 million). The plant manufactures APIs and formulations for oncology drugs.
AMRI extends API supply deal with Shire
Albany Molecular Research Inc. (AMRI; Albany) says it has entered into a multiyear active pharmaceutical ingredient (API) supply agreement for an undisclosed product with Shire US Manufacturing (Owings Mills, MD), a subsidiary of specialty biopharmaceutical company Shire (Dublin). The terms of the deal were not disclosed. The agreement extends a previously existing agreement between the two companies, AMRI says. Shire focuses its business on behavioral health, gastrointestinal diseases, rare diseases, and regenerative medicine, AMRI says.
Sinochem and PTT Global Chemical sign cooperation deal for fine chemicals business
Sinochem (Beijing) says it has signed a memorandum of strategic cooperation, at Shanghai on 21 August, with PTT Global Chemical (Bangkok), Thailand's largest integrated petrochemical and refining company, under which both companies will strengthen their strategic cooperation in the field of fine chemicals. Further details of the deal were not disclosed.
DKSH signs distribution deal with Israeli pharma and personal care ingredients firm
Distribution company DKSH (Zurich) says it has entered into a distribution agreement with Tagra (Netanya, Israel), a producer of stabilized active ingredients, covering China, India, Korea, Philippines, Thailand, and Vietnam. DKSH says it has been appointed as distributor for Tagra’s range of encapsulated actives, oils, and pigments. The products are developed and produced by applying Tagra’s manufacturing technology, Release On Demand (RND), which seals each microcapped ingredient from chemical and cross-link reactions, degradation, color change, or loss of potency during production and for extended periods thereafter. DKSH provides marketing, sales, logistics, and distribution services to Tagra under the deal.
Lonza and OncoMed sign process development and manufacturing deal
Lonza says it has signed an agreement with OncoMed Pharmaceuticals (Redwood City, CA), a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, for the development and manufacture of OncoMed’s pipeline of anticancer stem-cell therapeutics. Lonza will produce material at its mammalian manufacturing facility at Slough, UK, under the deal. The multiproduct GS system license provides access to Lonza’s GS Gene Expression System and Version 8 Media and Feeds manufacturing platform.
Pfizer to acquire NextWave Pharmaceuticals for $700 million
Pfizer says it will acquire NextWave Pharmaceuticals (Cupertino, CA), a privately held specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention-deficit/hyperactivity disorder and related central nervous system disorders. Pfizer had previously entered into an option and merger agreement with NextWave during the second quarter of 2012 and made an option payment of $20 million. Pfizer is now exercising its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWave’s shareholders at the closing of the transaction, and NextWave’s shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones. The transaction is expected to close later this year.
Avantor signs development agreement with Rubicon Research for pharma excipients
Avantor Performance Materials (Center Valley, PA) has signed a collaboration agreement with Rubicon Research (Mumbai) to develop, manufacture, and market products for the functional excipient market in pharmaceuticals. The companies plan to develop a novel gastroretentive excipient that can enable molecule delivery with a window of absorption, allowing targeted delivery and a therapeutic advantage with more options for the pharmaceutical excipient segment.